LFCR: Revenue and profit declined, but cost cuts and new wins support strong long-term growth outlookQuartr·6 hours agoLFCR+2.41%
LFCR: Revenue and profit declined, with liquidity sufficient but major preferred stock redemptions loomingQuartr·8 hours agoLFCR+2.41%
LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmedQuartr·8 hours agoLFCR+2.41%
Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 millionPUBT·8 hours agoLFCR+2.41%
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate UpdateUnusual Whales·8 hours agoLFCR+2.41%
Zacks Research Upgrades Lifecore Biomedical (NASDAQ:LFCR) to HoldMarket Beat·Jul 31 at 06:00 AMLFCR+2.41%
Lifecore Biomedical (LFCR) Expected to Announce Earnings on WednesdayMarket Beat·Jul 29 at 04:26 AMLFCR+2.41%
Lifecore Biomedical Signs Three New Customer Agreements | LFCR Stock NewsStockTitan·Jul 27 at 10:05 PMLFCR+2.41%
Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026TradingView·Jul 2 at 04:23 PMLFCR+2.41%
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company | LFCR Stock NewsStockTitan·Jun 14 at 10:05 PMLFCR+2.41%
